ESRD [7] , and this is at least partly due to disease recurrence.
IgAN may recur in the renal allograft in 9-61% of patients [8] . Recurrent disease was thought to have little impact on graft outcomes [9] . However, recent retrospective studies with longer duration of follow-up suggest that recurrent disease contributes substantially to allograft damage [6, 10, 11] . Risk factors for recurrence include presence of specific HLA genotypes, zero mismatch kidneys, high serum IgA levels, choice of induction therapy, choice of maintenance immunosuppression and duration of follow-up after transplant [12] [13] [14] [15] [16] . Post-transplant crescentic IgAN confers poorer allograft outcomes compared to post-transplant recurrence of non-crescentic IgAN [17, 18] . Most studies assessing the predictors of recurrent IgAN have focused on post-transplant clinical features. Improving clinicians' ability to estimate risk of recurrence prior to the transplant would be useful, particularly for counseling patients and designing management strategies.
Here we investigated the pre-transplant clinical and biopsy features of patients with IgAN who received renal transplants at Columbia University Medical Center (CUMC) from 2001 to 2012 and compare the characteristics and graft outcomes of patients with IgAN recurrence to those without recurrent disease.
Methods

Subjects
During the period from January 2001 through December 2012, 2,256 adult ( ≥ 18 years) patients with unique medical record numbers underwent renal transplantation at CUMC, including 150 patients with ESRD resulting from biopsy-documented IgAN. Only patients whose native kidney biopsies were read or reviewed at CUMC were included in this study. Secondary IgAN and SLE were excluded by history and clinical features. One patient had a history of Henoch-Schonlein purpura and IgAN on biopsy. Clinical and pathology data for 62 of the 150 patients was retrospectively reviewed. Patients were stratified into 2 groups, IgAN recurrence and no-IgAN recurrence for comparison of risk factors.
Histopathological Evaluation
All native biopsies were processed by standard techniques for light microscopy, immunofluorescence (IF) and electron microscopy (EM). Each biopsy was independently re-reviewed and scored by a single pathologist (P.E.R.). The diagnosis of IgAN was based on the presence of dominant or codominant staining for IgA by IF, with confirmatory EM findings of electron dense deposits in the majority of cases. Each biopsy was graded according to the Oxford classification ('MEST'), including scores for mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental glomerulosclerosis (S) and tubulointerstitial fibrosis (T) [19] . Crescents were categorized as cellular, fibrocellular or fibrous. Burden of crescents was calculated for each biopsy as the percentage of nonsclerotic glomeruli with cellular or fibrocellular crescents among all open glomeruli. Purely fibrous crescents were excluded from the numerator due to the lack of consensus in identifying fibrous crescents, and globally sclerotic glomeruli were excluded from the denominator.
Outcomes and Definitions
The primary outcome was time to recurrence of IgAN. The 2 secondary outcomes were (1) composite of doubling of serum creatinine (compared to post-transplant nadir) or allograft failure and (2) recurrent IgAN as a cause of allograft dysfunction (determined by the treating clinician with concurrence by the pathologist). We chose recurrence as the primary outcome because this can be diagnosed on biopsy and analyzed in an objective time-toevent fashion.
Pre-transplant variables that were collected included demographic data (age, gender, ethnicity), clinical presentation at time of biopsy, time from first biopsy to ESRD (defined as initiation of dialysis or transplantation) and duration of dialysis. Annualized loss of eGFR may have been a more meaningful measure of pretransplant disease activity [20] ; however, creatinine at the time of biopsy was not consistently documented. Post-transplantation data included allograft type (living vs. deceased donor), induction and maintenance immunosuppression, biopsy proven allograft rejection and grade, BK viremia and/or nephropathy, occurrence of proteinuria, nephrotic syndrome (defined as proteinuria >3.5 g per gram of creatinine, hypoalbuminemia and clinical documentation), hypertension (defined as BP >140/90 mm Hg or need for anti-hypertensives to achieve a BP of <140/90 mm Hg), graft loss (defined as return to dialysis or re-transplantation) and mortality.
Statistical Analysis
Descriptive statistics for continuous variables are presented as the mean ± SD if parametric, or median and interquartile range if non-parametric. For categorical variables, data are presented as count with percentage. Inter-group comparisons were made by Student's t test for normally distributed continuous variables, the Mann-Whitney U test for nonparametric continuous variables and Fisher's exact test for categorical variables. Univariate and multivariate Cox proportional hazards models were created for the time-dependent outcomes of recurrent IgAN and the composite of allograft failure or doubling creatinine. Logistic regression models were created for the outcome of recurrent IgAN as a cause of allograft dysfunction. All p values were 2-tailed and values <0.05 were considered statistically significant. Analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, N.C., USA).
Results
Clinical Characteristics Pre-Transplant
We reviewed the charts and original native kidney biopsies of 62 IgAN patients who received a transplant at our center and whose native biopsies had been read at our center. Of these 62 patients, 14 had recurrent IgAN in the allograft. Baseline characteristics of the cohort, in-cluding demographics and biopsy features from the native diagnostic biopsy, are presented in table 1 . Those who experienced recurrent disease were significantly younger at the time of native kidney biopsy than those who did not have recurrence (29 vs . 41 years, p < 0.0009). Black race and Hispanic ethnicity composed a higher proportion of the recurrent disease group than the norecurrence group. Progression from native kidney biopsy to ESRD was significantly more rapid in those who developed post-transplant IgAN recurrence versus in those who did not have recurrence (median 808 vs. 1,325 days, p = 0.02).
Histopathological Characteristics
There were no differences in MEST classification, percent interstitial fibrosis and tubular atrophy, foot process effacement on native kidney biopsy in those who had post-transplant IgAN recurrence versus in those with no recurrence ( table 1 ). All 62 patients were positive for the Oxford 'M' classifier of mesangial hypercellularity. Of the 62 native biopsies, 47% had <10% crescents, 29% had 10-29% crescents, 11% had 30-49% crescents and 13% had ≥ 50% crescents. Of those who had recurrent IgAN, the median percentage of open glomeruli containing cellular or fibrocellular crescents on native biopsy was 28% compared to 0% in those without recurrent disease (p = 0.0002). The distribution of crescents is shown in figure 1 . Among those with recurrent IgAN, 13 of 14 (93%) pa- Values are presented as number (%), mean ± SD, or median (IQR). * Thirty three patients received dialysis prior to transplant, 9 had recurrent IgAN and 24 did not. tients had at least 10% crescents on their native biopsies, and among those who did not recur only 20 of 48 patients (42%) had at least 10% crescents on their native biopsies (p = 0.007).
Clinical Characteristics Post-Transplant
Characteristics of the kidney transplants and posttransplant course are summarized in table 2 . Age at transplant was significantly lower in those who had recurrent IgAN compared to those who had no recurrence (mean 32.5 vs. 45.7 years, p < 0.01). Exposure to immunosuppression was similar between the groups. Rejection (either cellular or humoral), calcineurin toxicity (as documented in notes or pathology) and BK viremia was no different between the 2 groups. Nadir creatinine (1.6 vs. 1.17, p = 0.005) and creatinine at last follow-up (2.01 vs. 1.21, p = 0.001) were significantly higher in those with recurrent IgAN.
Recurrence and Treatment
Mean time to diagnosis of recurrent IgAN on allograft biopsy was 2.75 years after transplant (median 1.25 years). At the time of recurrence, the median proteinuria was 590 mg/g creatinine and the median serum creatinine was 2.2 g/dl. Of the 14 recurrences, 9 patients did not receive specific therapy beyond standard transplant immunosuppression, 2 patients received high-dose corticosteroid therapy alone, 2 patients received corticosteroid therapy and then rituximab therapy for a second recurrence and 1 patient received corticosteroid therapy plus rituximab therapy for a second recurrence plus ACTH for a third recurrence.
Primary Outcome
Univariate hazards ratios (HRs) for the primary outcome of time to recurrent IgAN after transplant are presented in table 3 . By univariate analyses, significant pre- Figure 2 a shows Kaplan-Meier curves for time to recurrent IgAN for those with <10 versus ≥ 10% crescents on native biopsy. On multivariate analysis, significant predictors of recurrent IgAN included age at diagnosis (HR 0.911, 95% CI 0.85-0.98), burden of crescents on native biopsy (HR 1.21 per 10% increase in crescents, 95% CI 1.00-1.47) and allograft rejection (HR 3.59, 95% CI 1.10-11.7), after adjusting for sex, ethnicity, time to ESRD, Oxford 'E' lesion on native biopsy, steroid use and angiotensin-convertingenzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) use post-transplant.
Secondary Outcomes
For the composite secondary outcome of doubling of serum creatinine after transplant or allograft failure, significant predictors in univariate Cox analyses included allograft rejection (HR 6.50, 95% CI 1.97-21.4), recurrent IgAN (HR 4.94, 95% CI 1.56-15.6) and nadir serum creatinine (HR 2.49 per each 0.5 g/dl increase, 95% CI 1.48-4.18). On multivariate analysis, the only significant predictors of the composite outcome were allograft rejection (HR 4.76, 95% CI 1.40-16.1) and nadir serum creatinine (HR 2.36 per each 0.5 g/dl increase, 95% CI 1.29-4.33), whereas recurrent IgAN was no longer a significant predictor. Burden of crescents did not significantly predict the composite outcome (univariate p = 0.36). Figure 2 b shows Kaplan-Meier curves for time to the composite outcome are shown for the group with <10 versus ≥ 10% crescents on native biopsy.
For the secondary outcome of recurrent IgAN as a cause of allograft dysfunction, univariate logistic regression showed significant associations with age at diagnosis (OR 0.89 per year, 95% CI 0.82-0.97), burden of crescents on native biopsy (OR 1.52 per 10% increase in crescents, 95% CI 1.13-2.02) and the presence of the Oxford 'E' lesion on native biopsy (OR 12.3, 95% CI 1.45-104). There was a suggestion of a protective effect with the use of rabbit anti-thymocyte globulin induction, albeit not reaching statistical significance (OR 0.19, 95% CI 0.03-1.04, p = 0.06). Variables that were not significantly associated with recurrent IgAN as a cause of allograft dysfunction included sex, race/ethnicity, preemptive transplant, liv- 
Discussion
We retrospectively analyzed a cohort of patients with IgAN who had native biopsies reviewed and underwent transplantation at CUMC. We compared the pre-transplant clinical and biopsy features of patients with recurrent IgAN with those who had no recurrence. We found that patients who developed recurrent IgAN were younger and had a more rapid progression to ESRD from their native disease. On multivariable analysis, predictors of recurrent IgAN were younger age, burden of crescents in the native kidney biopsy and allograft rejection. Recurrent IgAN was itself a predictor of doubling the serum creatinine and graft failure.
Though the rate of recurrence of IgAN is high (9-61% in the literature; 22.5% in this study), the rate of graft loss due to IgAN is thought to be low (3-4%) [8, 21] . Moroni et al. [11] analyzed the post-transplant outcomes of 190 patients with IgAN transplanted between 1981 and 2010. The rate of IgAN recurrence was 37.2%. Of these patients, about half experienced allograft loss and about half of the graft losses were due to recurrent IgAN. In univariate analysis, predictors of IgAN recurrence included year of transplant, younger age of recipient, maintenance immunosuppression without mycophenolate and use of <3 immunosuppressive agents. IgAN was an independent predictor of worse graft outcomes compared to non-diabetic controls. Choy et al. [10] examined the post-transplant outcomes of 75 patients with IgAN transplanted between 1984 and 2001 and found recurrent disease in 19% of patients. Of these patients, roughly a third of the patients had graft failure of which 60% were due to IgAN. Patients with IgAN had superior outcomes compared to controls without IgAN up until 12 years post-transplant when patients with IgAN had poorer graft outcomes. Similar to our study, Choy et al. [10] did not find donor type (living vs. deceased) and immunosuppression to be significant predictors of recurrence.
Clayton et al . [14] found recurrent IgAN as the cause of graft loss in 12.6% of patients transplanted for IgAN. Interestingly, they also found that patients who were corticosteroid-free at one year were more likely to have graft loss from IgAN than patients who received corticosteroids. Our study did not find that long-term (>1 year) use of corticosteroids reduced the risk of recurrence. We found a suggestion that anti-thymocyte globulin induction was associated with a longer time to recurrence compared to other types of induction (mostly basiliximab in this cohort). While this HR did not reach statistical significance, the effect size was clinically important, and in line with the findings of Berthoux et al . [22] who also found a protective effect with anti-thymocyte globulin.
Our study found that a greater burden of crescents on the native biopsy was associated with a shorter time to recurrence of IgAN post-transplant, and was also associated with a greater likelihood that the recurrent IgAN was pathogenic. We did not find that the burden of native crescents affected the composite outcome of doubling serum creatinine or allograft failure, which appeared to be largely driven by nadir creatinine (likely a proxy for allograft quality) and subsequent rejection. Our findings support the hypothesis that crescentic IgAN represents a more severe and aggressive form of disease, and thus, the pathophysiologic process leading to severe disease in the native kidney may lead to more aggressive recurrent disease in the transplanted kidney. In native IgAN, higher grades of proteinuria, hypertension and impaired kidney function are predictors of poor clinical outcomes [23] . However, we did not find these variables to be of significant value in predicting post-transplant recurrence. Thus, we hypothesize that crescents may be more indicative of immunologic disease activity, and thus recurrence risk, while these other factors may be confounded by disease chronicity. Clinically, patients with crescentic IgAN have a higher incidence of hypertension and nephrotic syndrome [24, 25] . In IgAN, crescents are associated with decreased renal survival, with an inverse correlation between the number of crescents and duration of renal survival [26, 27] . Lv et al. [28] found that in crescentic IgAN, defined as >50% crescents, progression to ESRD was as high as 70% at 5 years. Though the prognostic value of crescents was not systematically assessed in the Oxford cohort [29] due to low prevalence, other retrospective studies that have sought to investigate the prognostic value of crescents when added to the MEST score show conflicting results [27, 30, 31] . Moreover, the percent of crescents that define a biopsy as crescentic IgAN has been variably defined, ranging from any crescents to 50% glomerular involvement [27, 30, 32] . The largest systematic review and meta-analysis to examine the Oxford classification found that the presence of any crescent had independent prognostic importance, and the authors proposed adding a 'C' lesion (for any crescent) to the classification [33] . Our study supports the association of crescents with adverse outcomes, and further suggests a dose effect where a greater percentage of crescentic glomeruli are associated with higher risks of pathogenic recurrence.
There are several limitations of our study besides its retrospective design and single center design. The sample size is small with only 62 patients as we designed the study to include only those who had their native biopsies reviewed at Columbia. A larger study including multiple centers would have sacrificed the ability to examine histology and other variables in detail. Because protocol biopsies were not done routinely, subclinical recurrent IgAN cannot be excluded in the 31% of patients with 'no recurrence' who had not undergone renal allograft biopsy. Similarly, all subjects with recurrent IgAN had a forcause biopsy for allogfraft dysfunction, and thus, this group was likely enriched with rejection events. Our finding of an association between allograft rejection and time to recurrent IgAN was likely due to a confounding association. We found that Hispanic ethnicity and black race were more prevalent in the recurrent IgAN group, and that black race predicted recurrent IgAN on univariate analysis, but this was based on small numbers (only 4 black patients in the study, all of whom recurred.) Other studies have produced conflicting data on whether black race portends worse prognosis in IgAN [34 , 35] . A strength of the study is that all patients received transplants after 2001 which makes for a more standardized induction and maintenance immunosuppression regimen compared to previous studies that included patients from prior eras.
Our study adds to the growing literature examining the impact of recurrent IgAN on long-term allograft outcomes. Importantly, we have found that younger age at diagnosis and crescentic disease in the native kidney are strongly associated with earlier post-transplant IgAN recurrence. This may be helpful in counseling IgAN patients on their expectations prior to transplant, on selecting post-transplant immunosuppressive regimens and/or in designing strategies for managing recurrent disease. In addition to histologic and clinical predictors of recurrence, future prospective studies may include measurements of novel biomarkers of disease activity to predict recurrent IgAN [36] . Continuing to hone our predictive ability is important, given our findings and those of others that suggest that recurrent IgAN is associated with poorer allograft outcomes.
Disclosure Statement
